Gerhard Burits takes on new role at the ELATEC Group / RFID specialist ELATEC: New management duo with many years of experience
23.7.2024 09:00:00 CEST | news aktuell GmbH | Press release

Munich, July 23, 2024 – Gerhard Burits expands his responsibilities and assumes the role of CEO of the ELATEC Group. Thanks to his in-depth knowledge of the company structure and his strategic foresight, he is ideally qualified to reinforce ELATEC’s position as an innovation leader in global competition. The management board will have joint leaders at the helm: Also on board is Paul Massey, who, as CEO of ELATEC Inc., is now also taking on the role of COO of the ELATEC Group and contributing his international expertise to a greater extent.
Gerhard Burits, who joined the company in June 2020 as Chief Financial Officer (CFO), has been appointed Chief Executive Officer (CEO) of ELATEC GmbH. Over the past four years, he has made a significant contribution as CFO to financial stability and international growth, positioning ELATEC excellently with his strategic expertise. As CEO, he is now determined to reinforce the ELATEC Group’s technological lead, strengthen its presence on the global market, and thus initiate the next growth spurt. Personal thanks go to the previous CEO, Robert Helgerth, who is going into a well-deserved retirement after a successful career. Under his leadership, ELATEC has strengthened and solidified the basis for further growth.
Global expansion course with quality ‘Made in Germany’
The ELATEC Group will continue to remain true to its core areas of expertise under the new leadership: “Quality ‘Made in Germany’ remains of crucial importance to us while we adapt agilely to changing market requirements and continue to offer top service quality,” says CEO Gerhard Burits. As Chief Operating Officer (COO), Paul Massey will work closely with Gerhard Burits to drive forward the company’s global strategy and promote international expansion.
ELATEC’s mission: Technological leadership through innovation and employee strength
Gerhard Burits, CEO of the ELATEC Group, emphasizes: “Our mission is to further develop ELATEC as a technology leader. The key to that lies in the innovative strength of our core areas of expertise and in promoting our employees. A positive corporate culture with team spirit and flat hierarchies, characterized by ELATEC expertise, is important to us. That lays the foundation for us to adapt flexibly to changing market requirements and expand our technological lead.”
Paul Massey adds: “Our aim is to consolidate and expand our position as a leading provider of innovative and future-proof access systems. We will help our customers through our innovative solutions and world-class service to be successful in a rapidly changing environment.”
Available images for download:
https://elatec.me/3L6XuF1
- Picture is available at AP -
About ELATEC
ELATEC is a leading global provider of user authentication and identification solutions. Together with its global partners, the company develops innovative and future-proof access systems for its customers. With the interplay of pioneering multi-frequency readers, advanced authentication software and world-class service and support, ELATEC is driving the digital transformation of its customers and partners. The breakthrough solutions that result ensure an optimal user experience and are used in a wide range of applications and industries where secure and convenient access is required – including access control, fleet management, machine authentication, electric vehicle charging, secure printing, kiosks and more. Founded in 1988 and headquartered in Munich, Germany, the company is now represented at 19 locations worldwide.
For more information: www.elatec.com
Press contact ELATEC GmbH:
Anna Vanessa Evertz
Zeppelinstraße 1
82178 Puchheim
Germany
Tel.: +49895529961-180
E-mail: a.evertz@elatec.com
Press contact agency:
Maisberger GmbH
Claudius-Keller-Str. 3c
81669 Munich
Germany
E-mail: elatec@maisberger.com
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
